2.76
0.82 (42.07%)
| Previous Close | 1.94 |
| Open | 2.00 |
| Volume | 843,663 |
| Avg. Volume (3M) | 11,128 |
| Market Cap | 31,569,746 |
| Price / Sales | 6.30 |
| Price / Book | 1.39 |
| 52 Weeks Range | |
| Earnings Date | 28 May 2025 |
| Operating Margin (TTM) | -80.19% |
| Diluted EPS (TTM) | -1.19 |
| Quarterly Revenue Growth (YOY) | 1,996.90% |
| Total Debt/Equity (MRQ) | 22.93% |
| Current Ratio (MRQ) | 4.48 |
| Operating Cash Flow (TTM) | -12.01 M |
| Levered Free Cash Flow (TTM) | -7.67 M |
| Return on Assets (TTM) | -38.34% |
| Return on Equity (TTM) | -75.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | CollPlant Biotechnologies Ltd. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.75 |
|
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.16% |
| % Held by Institutions | 12.23% |
| 52 Weeks Range | ||
| Median | 12.00 (335.40%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 30 May 2025 | 12.00 (335.40%) | Buy | 3.18 |
| 28 May 2025 | 12.00 (335.40%) | Buy | 3.40 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jun 2025 | Announcement | COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES |
| 04 Jun 2025 | Announcement | COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS |
| 30 May 2025 | Announcement | COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES |
| 28 May 2025 | Announcement | COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE |
| 14 May 2025 | Announcement | COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS |
| 15 Apr 2025 | Announcement | CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |